<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T21:48:13Z</responseDate>
  <request identifier="oai:figshare.com:article/33959483" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33959483</identifier>
        <datestamp>2026-09-21T18:06:28Z</datestamp>
        <setSpec>category_12</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_811</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_106</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Model parameters, biological interpretations, baseline values, and corresponding sources used in the numerical simulations of the cervical cancer–oncolytic virotherapy model.&lt;/p&gt;</dc:title>
          <dc:creator>Salil Ghosh (641220)</dc:creator>
          <dc:creator>Amit Kumar Bag (25085156)</dc:creator>
          <dc:creator>Satyajit Mukherjee (4860136)</dc:creator>
          <dc:creator>Xianbing Cao (17696900)</dc:creator>
          <dc:creator>Amarnath Chatterjee (25085159)</dc:creator>
          <dc:creator>Priti Kumar Roy (20256639)</dc:creator>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Mathematical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Science Policy</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>risk human papillomavirus</dc:subject>
          <dc:subject>quantitative treatment assessment</dc:subject>
          <dc:subject>promising targeted strategy</dc:subject>
          <dc:subject>optimal control framework</dc:subject>
          <dc:subject>fundamental qualitative properties</dc:subject>
          <dc:subject>free viral particles</dc:subject>
          <dc:subject>based evidences justify</dc:subject>
          <dc:subject>balancing treatment cost</dc:subject>
          <dc:subject>analytical findings obtained</dc:subject>
          <dc:subject>infected epithelial cells</dc:subject>
          <dc:subject>induced cervical cancer</dc:subject>
          <dc:subject>deterministic mathematical model</dc:subject>
          <dc:subject>dependent therapeutic strategies</dc:subject>
          <dc:subject>infected cancer cells</dc:subject>
          <dc:subject>optimizing combined virotherapy</dc:subject>
          <dc:subject>interactions among hpv</dc:subject>
          <dc:subject>cancer cells</dc:subject>
          <dc:subject>therapeutic parameters</dc:subject>
          <dc:subject>model captures</dc:subject>
          <dc:subject>strongly associated</dc:subject>
          <dc:subject>standalone intervention</dc:subject>
          <dc:subject>specific cytotoxic</dc:subject>
          <dc:subject>relative influence</dc:subject>
          <dc:subject>recent times</dc:subject>
          <dc:subject>providing insight</dc:subject>
          <dc:subject>persistent infection</dc:subject>
          <dc:subject>performed using</dc:subject>
          <dc:subject>oncolytic virotherapy</dc:subject>
          <dc:subject>numerical simulation</dc:subject>
          <dc:subject>highlights parameters</dc:subject>
          <dc:subject>effective scheduling</dc:subject>
          <dc:subject>comparative advantages</dc:subject>
          <dc:subject>assess time</dc:subject>
          <dc:description>&lt;p&gt;Model parameters, biological interpretations, baseline values, and corresponding sources used in the numerical simulations of the cervical cancer–oncolytic virotherapy model.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-21T18:06:09Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pone.0342672.t001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_Model_parameters_biological_interpretations_baseline_values_and_corresponding_sources_used_in_the_numerical_simulations_of_the_cervical_cancer_oncolytic_virotherapy_model_p_/33959483</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
